Menu
Your Cart

Apostle MiniEnrich EMS Panel v1.0, 96 rxn

Apostle MiniEnrich EMS Panel v1.0, 96 rxn
Secured Shopping
Best security features
Apostle MiniEnrich EMS Panel v1.0, 96 rxn

Introduction

Apostle MiniEnrich EMS Panel v1.0 (Early Methylation for Screening) covers methylation gene sites related to nine major high-incidence cancers, including selected sites approved by the NMPA and FDA, as well as those reported in literature and patents. It encompasses nine types of cancers, including lung cancer, colorectal cancer, gastric cancer, liver cancer, breast cancer, carcinoma cancer, prostate cancer, cervical cancer, and ovarian cancer, involving 76 methylated candidate genes associated with carcinogenesis and tumor suppression, with over 2,000 CpG sites. The probe design covers approximately 20 Kb of the human genome, providing comprehensive and accurate support for methylation early screening.

 

Species of Cancer

Biomarker

Lung Cancer

SCT, HOXA7, RASSF1, SHOX2, PTGER4

Colorectal Carcinoma

NDRG4, BCAT1, SEPTIN9, BMP3, TFPI2, SDC2, SFRP2

Gastric Cancer

SEPTIN9, RNF180, TCF4, RPRM, SDC2, TERT

Liver Cancer

SCN48, BDH1, HOXA10, PLAC8, BMPR1A, TEPP, SPACA6, MIXL1, TSC22D1

Breast Cancer

CDO1, PITX2, GSTP1, GP5, APC

Carcinoma Cancer

SOX1, GALR1, DMRTA2, EVX2, SOX17, DCHS2, TWIST1, TBX5, HOXA11, SIM2, LHX2

Prostatic Cancer

CCND2, CDH1, MCAM, PENK, PITX2, PTGS2, RARB, LINC02028, SLCO3A1, HES5, TPM4, FHAD1, SOX1-OT, IGFBP3, ZNF154, FEZF2, APC

Cervical Cancer

SOX1, PAX1, JAM3, TAFA4, ASTN1, DLX1, ITGA4, RXFP3, SOX17

Ovarian Cancer

PCDHB18P, CDO1, HOXA9, LYPD5, CDH13, FOXD3, ZNF671, HOXA11, FBXO32, OPCML, BLACAT1, LRRC41, GNE, FAIM2, CAPN2, SIM2

 

Information

Cat #

NA003212

Capacity

96 rxn

Performance

Check information page

Protocol



$9,600.00
Tags: EMS Panel
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.